63 related articles for article (PubMed ID: 33724863)
21. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Nero C; Ciccarone F; Pietragalla A; Duranti S; Daniele G; Salutari V; Carbone MV; Scambia G; Lorusso D
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803954
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic and Predictive Role of Somatic
Toss A; Piombino C; Tenedini E; Bologna A; Gasparini E; Tarantino V; Filieri ME; Cottafavi L; Giovanardi F; Madrigali S; Civallero M; Marcheselli L; Marchi I; Domati F; Venturelli M; Barbieri E; Grandi G; Tagliafico E; Cortesi L
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33801055
[TBL] [Abstract][Full Text] [Related]
23. Germline Mutations in Other Homologous Recombination Repair-Related Genes Than
Cortesi L; Piombino C; Toss A
J Pers Med; 2021 Mar; 11(4):. PubMed ID: 33800556
[TBL] [Abstract][Full Text] [Related]
24. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
[TBL] [Abstract][Full Text] [Related]
25. Mutations in
Fasching PA; Yadav S; Hu C; Wunderle M; Häberle L; Hart SN; Rübner M; Polley EC; Lee KY; Gnanaolivu RD; Hadji P; Hübner H; Tesch H; Ettl J; Overkamp F; Lux MP; Ekici AB; Volz B; Uhrig S; Lüftner D; Wallwiener M; Müller V; Belleville E; Untch M; Kolberg HC; Beckmann MW; Reis A; Hartmann A; Janni W; Wimberger P; Taran FA; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Hartkopf AD; Couch FJ
J Clin Oncol; 2021 May; 39(15):1619-1630. PubMed ID: 33780288
[TBL] [Abstract][Full Text] [Related]
26. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
27. Overview of recent advances in metastatic triple negative breast cancer.
O'Reilly D; Sendi MA; Kelly CM
World J Clin Oncol; 2021 Mar; 12(3):164-182. PubMed ID: 33767972
[TBL] [Abstract][Full Text] [Related]
28. Early effects of BRCA1 mutations in the breast.
Seton-Rogers S
Nat Rev Cancer; 2021 May; 21(5):280. PubMed ID: 33762751
[No Abstract] [Full Text] [Related]
29. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Le Saux O; Vanacker H; Guermazi F; Carbonnaux M; Roméo C; Larrouquère L; Trédan O; Ray-Coquard I
Future Oncol; 2021 Jun; 17(18):2291-2304. PubMed ID: 33726504
[TBL] [Abstract][Full Text] [Related]
31. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
32. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
33. The results of multigene panel sequencing in Slovak HBOC families.
Konecny M; Kosova K; Tilandyova P; Wachsmannova L; Baldovic M; Krajcovic J; Patlevicova A; Markus J; Ciernikova S
Neoplasma; 2021 May; 68(3):652-664. PubMed ID: 33724863
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
35. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
36. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
